Kangtai Bio | Briefing, News, Analysis, Research, Data

Kangtai Bio

Kangtai Bio a famous international pharmaceutical company

Kangtai Bio is one of the first high-tech enterprises in Shenzhen, mainly engaged in the development, production and sales of biological products. It has a team of vaccine industry professionals who have made important breakthroughs in the research and development of new vaccines. The production line is imported from Merck, a famous international pharmaceutical company, and its safety and efficacy have been guaranteed, and the products have covered 31 provinces, municipalities and autonomous regions.

Sector

Healthcare

Industry

Biotech/Pharma

Sub-industry

Founded

Sept 8, 1992

HQ location

Guangdong, China

Legal name

Shenzhen Kangtai Biological Products Co., Ltd.

Website

http://www.biokangtai.com/

office@biokangtai.com

Employees

501-1000

All
News
Analysis
Research

Briefing Feb 16, 2023 12:51 PM · Healthcare

Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A

Briefing Feb 07, 2023 12:11 PM · Healthcare

ForLong Biotech Nets Over CNY 100 Mn in Series A

In-depth

Healthcare

Chinese Company Turned the Tables on Domestic Cell Culture Media Market

In this article, EqualOcean mainly introduce the history, competition, lead company, future trend in domestic cell culture media industry.

Feb 02, 2023 10:45 AM

Briefing Feb 07, 2023 10:59 AM · Healthcare

CytoCan Corp. Nets CNY 10 Mn in Seed Round

Briefing Jan 30, 2023 10:44 AM · Healthcare

Levostar Completes Pre-A Financing Round to Further Invest in CGT

Research

Healthcare

Digital Therapeutics - Revolution of the healthcare system

Nov 16, 2022 05:19 PM

Research

Healthcare

2022 China AI Health 30 Report

Nov 07, 2022 04:27 PM

Research

Healthcare

2022 China’s Healthcare Industry: An Introductory Handbook

Aug 29, 2022 05:45 PM

Research

Healthcare, Financials, Technology

WIA2020 | 30 Tech Entrepreneurs in China

Apr 22, 2021 03:11 PM

Briefing Jan 18, 2023 10:59 AM · Healthcare

BlissBio Nets Over CNY 100 Mn in Series B+

Briefing Jun 27, 2022 06:44 PM · Technology | Healthcare

Zhongxin fluoromaterials: it is planned to acquire 51% equity of Jiangxi Exxon through equity transfer and cash capital increase

Briefing Jan 28, 2022 07:49 PM · Technology | Healthcare

Kangtai biology: the net profit in 2021 is expected to increase by 76.68% - 106.13% year-on-year

Briefing Jan 23, 2022 05:59 PM · Healthcare

Kangtai biology: CDE starts the on-site verification of the registration of freeze-dried human rabies vaccine (human diploid cells)

Healthcare

Reforgene Completes Pre-B Round Financing of CNY Hundreds of Millions

EqualOcean learned that Reforgene Medicine (瑞风生物) recently announced the completion of Pre-B round financing of CNY hundreds of millions.

May 04, 2023 02:05 PM

Healthcare

Joe Future Food Completes A+ Round Financing of CNY Tens of Million

Cell-Cultured Meat Leader, Joe Future Food (周子未来), completes A+ round financing of CNY tens of million.

Apr 28, 2023 05:13 PM

Briefing Sep 17, 2021 02:24 PM · Technology | Consumer Staples

Before the festival, the market of "drinking and taking medicine" reappeared, and the food and beverage ETF (515170) rose 2.5%

Briefing Sep 17, 2021 12:03 PM · Technology | Healthcare

2021 China Internet development innovation and investment competition (Changsha) public welfare project and Beidou Innovation Application Challenge kicked off

Briefing Sep 05, 2021 05:52 PM · Healthcare | Financials

Anxin strategy: high prosperity configuration and low position trading

Healthcare

Tripod, the New CRO, Completes C Round Financing of RMB Hundreds of Mn

Tripod Preclinical Research Laboratories Co., Ltd. (鼎泰集团) announced the completion of C round financing of RMB hundreds of million.

Apr 28, 2023 12:07 PM

Technology, Consumer Staples, Healthcare

HastenPharma Secures USD 315 Mn in Financing to Focus on M&A Business and R&D

Anhui-based biopharmaceutical company HastenPharma(海森生物) raised USD 315 million in funding on April 20, with the financing round aimed at focusing on future mergers and acquisitions and product innovation, according to EqualOcean.

Apr 23, 2023 12:20 PM

Briefing Aug 06, 2021 01:08 PM · Technology | Healthcare | Financials

Will Huawei's server business be packaged for sale? Huawei insiders: business is affected but will not give up

Briefing Jul 23, 2021 10:13 AM · Healthcare

Pharmaceutical and biological stocks fell sharply in early trading

Briefing Jul 19, 2021 05:45 PM · Technology | Healthcare | Financials

Samsung Xincai replied to the regulatory letter: there is no direct or indirect misappropriation of raised funds through entrusted loans

Briefing May 26, 2021 10:06 AM · Healthcare | Financials

Vaccine stocks weakened in early trading

EqualOcean Analysis